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Abstract
Genome-wide association studies (GWAS) have demonstrated the ability to identify the strongest causal common variants
in complex human diseases. However, to date, the massive data generated from GWAS have not been maximally explored
to identify true associations that fail to meet the stringent level of association required to achieve genome-wide
significance. Genetics of gene expression (GGE) studies have shown promise towards identifying DNA variations associated
with disease and providing a path to functionally characterize findings from GWAS. Here, we present the first empiric study
to systematically characterize the set of single nucleotide polymorphisms associated with expression (eSNPs) in liver,
subcutaneous fat, and omental fat tissues, demonstrating these eSNPs are significantly more enriched for SNPs that
associate with type 2 diabetes (T2D) in three large-scale GWAS than a matched set of randomly selected SNPs. This
enrichment for T2D association increases as we restrict to eSNPs that correspond to genes comprising gene networks
constructed from adipose gene expression data isolated from a mouse population segregating a T2D phenotype. Finally, by
restricting to eSNPs corresponding to genes comprising an adipose subnetwork strongly predicted as causal for T2D, we
dramatically increased the enrichment for SNPs associated with T2D and were able to identify a functionally related set of
diabetes susceptibility genes. We identified and validated malic enzyme 1 (Me1) as a key regulator of this T2D subnetwork in
mouse and provided support for the association of this gene to T2D in humans. This integration of eSNPs and networks
provides a novel approach to identify disease susceptibility networks rather than the single SNPs or genes traditionally
identified through GWAS, thereby extracting additional value from the wealth of data currently being generated by GWAS.
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Introduction
Genome-wide association studies (GWAS) have revolutionized
our ability to identify the causal determinants for common
human diseases over the past several years, delivering an
unprecedented number of DNA loci associated with a diversity
of common human diseases like age-related macular degenera-
tion [1,2], Crohn’s disease [3], type 1 diabetes [3,4], coronary
artery disease [3,5], HIV-1 infection [6], and type 2 diabetes
(T2D) [3,7–10]. One interesting characteristic of single nucleotide
polymorphisms (SNPs) identified as associated with disease in
these studies is that the great majority do not affect the coding
sequence of genes, most often falling in introns or intergenic
regions [11]. As a result, GWAS do not necessarily lead directly
to the gene or genes in a given locus associated with disease, they
do not typically inform the broader context in which the disease
genes operate, and even in cases where the susceptibility gene is
identified, GWAS do not usually indicate whether you would
knock the gene down or activate it in order to treat the
corresponding disease. Therefore, GWAS on their own provide
limited insights into the mechanisms driving disease [12–14]. In
addition, the amount of genetic variation explained by GWAS for
a given disease is most often significantly less than the
heritabilities estimated for the disease. For example, a number
of studies estimate the genetic heritability for T2D to be as high
as 40%, but the 18 DNA loci identified for T2D to date account
for only ,3% of the variation in T2D [10]. This raises the
question of whether there are many more common DNA variants
with smaller effects that are not being identified in the GWAS
due to lack of power, whether there are many more rare variants
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with stronger effects that explain the missing variation, or some
combination of the two [11,15].
In fact, in the span of just a few short years in which large-scale
GWAS have been carried out, the realization that tractable drug
targets and clinically useful biomarkers of disease are not
immediately falling out of the data, has for some reduced the
enthusiasm for the GWAS approach, intensifying the debate over
whether GWAS are the best strategy to elucidate the causes of
disease [16–18]. Some have attempted to look for enrichments in
pre-defined sets of pathways defined by GO, KEGG or other
pathway sources and found common variants involved in T2D risk
are likely to occur in or near genes in multiple pathways [19]. One
clear and immediate task to provide further insights into GWAS is
to develop an understanding of the genetics of gene expression
(GGE) to facilitate a systems-based understanding of disease.
Recently, detailed GGE studies have provided a way to address
several of these GWAS limitations [13,14,20–22]. By mapping the
genetic architecture of gene expression in human populations,
GGE studies can provide functional support for candidate genes
within a given locus. This has been demonstrated a number of
times, but most recently in identifying SORT1, PSRC1, and
CELSR2 as candidate susceptibility genes for heart disease and
plasma lipid levels [14], and ORMDL3 as an asthma susceptibility
gene [20,23]. More generally, GGE studies provide the necessary
information to infer causal relationships among genes and between
genes and clinical traits, leading to whole gene networks that
provide a broader context within which to elucidate the biological
function of any given gene with respect to diseases of interest
[12–14,24,25].
One way GGE studies can impact interpretation of GWAS is by
providing a way to reduce the dimensionality of the DNA
variation space, limiting focus to those DNA variants that have
been associated with expression traits and testing whether such
SNPs are associated with disease [12]. The set of SNPs associated
with expression (eSNPs) in disease-relevant tissues can be
considered a functionally relevant subset of all SNPs across the
human genome, given they associate with a biologically relevant
event (gene expression). However, the extent to which eSNPs
inform on disease biology has not been comprehensively
characterized for any disease. In this paper, we systematically
examined whether eSNPs are more likely to associate with T2D
compared to SNPs that a priori have no association to biologically
relevant events. We assembled a comprehensive set of eSNPs
identified in two GGE study cohorts representing three tissues
[12]: liver, subcutaneous fat and omental fat tissues. Given the
metabolic relevance of these tissues and the large-scale GWAS
undertaken for T2D [26], we tested whether this set of eSNPs was
more likely to associate with T2D than randomly selected SNPs.
We further constructed a co-expression network from subcutane-
ous adipose tissue isolated from a mouse population segregating
T2D traits and asked whether eSNPs associated with genes
comprising these networks and sub-networks were enriched for
association with T2D (Figure 1). By comparing the relative
enrichments for association to T2D at these increasing levels of
granularity, we sought to identify disease-associated subnetworks
whose member genes might play important roles in T2D
pathogenesis.
Results
eSNPs Are Enriched for Association to T2D
We identified eSNPs from two GGE studies: 1) a liver tissue
cohort comprised of 427 individuals [12], and 2) a cohort
comprised of ,900 individuals from which liver, subcutaneous
and omental adipose tissues were collected from each individual.
The number of eSNPs from each tissue and the corresponding
cohort sample sizes are summarized in Table S1. To test whether
the eSNPs were enriched for association to T2D, we assembled
GWAS results from three previously published T2D studies: 1) the
Wellcome Trust Case Control Cohort (WTCCC) [3], 2) the
Diabetes Genetics Initiative (DGI) [7], and 3) the Diabetes
Genetics Replication And Meta-analysis (DIAGRAM) Consor-
tium [10], which combines the results from WTCCC, DGI, and
Finland–United States Investigation of NIDDM Genetics (FU-
SION) [8].
To assess whether these distributions were enriched for SNPs
associated with T2D, we empirically estimated the null distribu-
tion by randomly sampling 100,000 sets of SNPs from a set of
SNPs genotyped in each study (chosen from the full set of SNPs in
each study) such that the SNP set size, the location distribution of
the SNPs with respect to protein coding genes, and the minor
allele frequency (MAF) distribution were similar to that of the
eSNP set.
The distribution of T2D eSNP association p values from the
GWAS (referred to here as PT2D) differed significantly from the
null distribution in that the eSNP PT2D values were skewed
towards the significance end of the PT2D spectrum. For example,
in the DGI study, 6.2% of the eSNPs (241 out of 3,888 total) had
PT2D,0.05, compared to a mean of 5.2% (202 out of 3,888; 95%
confidence interval (CI): 4.6% to 5.8%) over the 100,000
randomly generated matched sets (Z= 3.16; p= 8.0061024,
Table 1, Figure 2), representing a 1.19 fold enrichment for SNPs
in the eSNP set over the random sets. In addition to testing for
enrichments of eSNPs with PT2D,0.05, we compared the overall
average PT2D of the eSNP set to randomly selected SNP sets
matched to the eSNP set with respect to location and MAF. The
results were similar to the enrichment observed for eSNPs with
PT2D,0.05 (Figure S1).
Because different SNP panels were used in the different GGE
and GWA studies, many of the eSNPs were not genotyped in any
of the T2D GWAS. Therefore, we recomputed the PT2D
distributions based on all SNPs in strong linkage disequilibrium
Author Summary
Genome-wide association studies (GWAS) seek to identify
loci in which changes in DNA are correlated with disease.
However, GWAS do not necessarily lead directly to genes
associated with disease, and they do not typically inform
the broader context in which disease genes operate,
thereby providing limited insights into the mechanisms
driving disease. One critical task to providing further
insights into GWAS is developing an understanding of the
genetics of gene expression (GGE). We present the first
empiric study demonstrating that SNPs in human cohorts
that associate with gene expression in liver and adipose
tissues are enriched for associating with Type 2 Diabetes
(T2D) in humans. By filtering ‘‘eSNPs’’ based on causal
gene networks defined in an experimental cross popula-
tion segregating T2D traits, we demonstrate a dramatically
increased enrichment of T2D SNPs that enhance our ability
to assess T2D risk. We demonstrate the utility of this
approach by identifying malic enzyme 1 (ME1) as a novel
T2D susceptibility gene in humans and then functionally
validating the causal connection between ME1 and T2D in
a mouse knockout model for Me1. This approach provides
a path to identifying disease susceptibility networks rather
than single SNPs or genes traditionally identified through
GWAS.
Networks of eSNPs
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(LD) with the eSNPs. A SNP was considered in strong LD with an
eSNP if the correlation between the two SNPs was .0.89. These
SNPs were considered to be representative of our eSNPs and were
included in the analysis set (referred to here as the expanded eSNP
set) in order to extract the most information from the GWAS data.
We again tested whether this expanded eSNP set was enriched for
SNPs associated with T2D by empirically estimating the null
distribution. For example, in the DGI study, 1,516 SNPs in the
expanded eSNP set of 24,220 SNPs (6.3%) had PT2D,0.05,
compared to an average of 1,279 SNPs (5.3%; [95% CI: 4.9% to
5.7%]) in the random sets (Z= 5.05; p= 2.1961027), representing
a 1.19-fold enrichment for SNPs in the expanded set over the
random sets. Similar enrichments were observed in the DGI and
WTCCC studies (Table 1, Figure 2).
Adipose Gene Network Enhances eSNP Association with
T2D
While the eSNP PT2D enrichments in liver, omental and
subcutaneous tissue were statistically significant, the enrichment
was modest (1.19 fold enrichment for the expanded eSNP set).
One explanation for this could be that these enrichments were
calculated using an eSNP set spanning three distinct tissues
without considering how the expression traits relate to networks
associated with disease. Therefore, even though the eSNPs
considered herein were derived from metabolically active tissues,
we considered the possibility that restricting attention to eSNPs
corresponding to expression traits in T2D-relevant tissues that are
most variable in populations segregating T2D traits may enhance
the enrichment for eSNPs associated with T2D.
Towards this end, we tested whether eSNPs corresponding to
genes comprising an adipose tissue gene network constructed from
an F2 intercross between C57BL/6 ob/ob and BTBR ob/ob mice
(referred to here as the B66BTBR cross) were enriched for
association with T2D. The B66BTBR cross has been previously
established as a model population for T2D [27]. While the
C57BL/6 ob/ob strain becomes obese and develops moderate
hyperglycemia, it is compensated by hyperinsulinemia, preventing
beta-cell failure and the development of a T2D phenotype. In
contrast, the BTBR ob/ob strain develops obesity, accompanied by
severe hyperglycemia and insulin resistance, ultimately resulting in
beta-cell failure and a severe T2D phenotype. Therefore, the gene
networks in T2D-relevant tissues in the B66BTBR mice have the
potential to provide insight into pathways and regulatory networks
in obesity-induced diabetes [28,29]. In this setting, we define a
gene network as a graphical model comprised of nodes and edges,
where the nodes represent gene expression traits or clinical traits,
and the edges represent significant, weighted correlations between
the corresponding two nodes (expression traits) [30]. Because gene
expression, DNA variations and T2D traits were all scored in
B66BTBR cross, there is the potential to identify tissue-specific
subnetworks that are causally associated with T2D traits, given
DNA variations can be treated as a perturbation on the gene
expression and clinical traits, thereby enabling the edges in the
Figure 1. Diagram depicting the process of filtering SNPs using eSNPs and disease associated networks.
doi:10.1371/journal.pgen.1000932.g001
Networks of eSNPs
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network to be directed [12,24,31–33]. Of the 39,600 genes
represented on the microarray used in this study, the upper 25
percent of the most differentially expressed genes were used as
input to construct the coexpression network [30]. We then
restricted our eSNP set to those omental adipose eSNPs
corresponding to genes in the adipose network that mapped to
human orthologs (referred to as the adipose eSNP set) and found
the expanded eSNP set significantly more enriched for T2D
Table 1. eSNP Set Enrichment Summary for the DIAGRAM, DGI and WTCCC GWAS.
DIAGRAM DGI WTCCC
Number Genotyped 16,801 3,888 4,047
All eSNPs % PT2D,0.05 (%) 6.63 6.20 6.72
% PT2D,0.05 from random set (95% CI) 5.70 (5.40, 6.00) 5.19 (4.56, 5.82) 5.94 (5.27, 6.60)
% PT2D,0.05 Fold Increase over random SNP sets(p) 1.16 (2.05610
29) 1.19 (8.0061024) 1.13 (1.0961022)
Number Genotyped 144,660 24,220 25,591
All expanded eSNPs % PT2D,0.05 (%) 7.34 6.26 7.50
% PT2D,0.05 from random set (95% CI) 6.12 (5.72, 6.52) 5.28 (4.90, 5.66) 6.43 (5.99, 6.87)
% PT2D,0.05 Fold Increase over random expanded SNP sets (p) 1.20 (1.33610
29) 1.19 (2.1961027) 1.17 (1.2261026)
Number Genotyped 19,853 3,342 3,539
Adipose network expanded eSNPs % PT2D,0.05 (%) 9.21 9.07 8.20
% PT2D,0.05 from random expanded eSNP set (95% CI) 7.30 (6.93, 7.65) 6.13 (5.31, 6.95) 7.40 (6.53, 8.26)
% PT2D,0.05 Fold Increase over random expanded eSNP sets (p) 1.26 (,10
216) 1.48 (1.10610212) 1.11 (3.4961021)
Number Genotyped 628 101 111
Adipose purple subnetwork
expanded eSNPs
% PT2D,0.05 (%) 13.22 36.63 10.81
% PT2D,0.05 from random adipose network expanded eSNP
set (95% CI)
9.21 (6.94, 11.50) 9.04 (3.44, 14.63) 8.20 (3.08, 13.29)
% PT2D,0.05 Fold Increase over random adipose network
expanded eSNP sets (p)
1.44 (2.9761024) 4.05 (,10216) 1.32 (1.5761021)
doi:10.1371/journal.pgen.1000932.t001
Figure 2. eSNP sets enriched for T2D associated SNPs in three GWAS. The Y axis shows the proportion of SNPs with PT2D,= 0.05. The PT2D
are from DIAGRAM, WTCCC, and DGI from left to right. In each GWAS cohort, from left to right, the 1st bar shows the observed proportion of
all studied SNPs; the 2nd bar shows the proportion of all eSNPs, the 3rd bar shows the proportion of the expanded eSNPs; the 4th bar shows the
proportion of the expanded adipose network eSNPs; and the 5th bar shows the proportion of the expanded T2D adipose causal subnetwork eSNPs. In
DIAGRAM study, the second bar is significantly higher than the first (p = 2.0561029), the third bar is higher than the second (p = 1.3361029), the
fourth is higher than the third (p,10216), and the fifth is higher than the fourth (p = 2.9761024). In WTCCC, the second bar is higher than the first
(p = 1.0961022), the third is higher than the second (p = 1.2261026), but the fourth and fifth bars are not significantly higher than the third (p = 0.35)
or fourth (p = 0.15), respectively. In the DGI study, the second bar is higher than the first (p = 8.061024), the third is higher than the second,
(p = 2.1961027), the fourth is higher than the third (p = 1.10610212), and the fifth is higher than the fourth (p,10216).
doi:10.1371/journal.pgen.1000932.g002
Networks of eSNPs
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associated SNPs compared to randomly selected eSNPs in the
DIAGRAM and DGI studies. In the DGI study, of the 3,342
expanded eSNPs from the adipose set considered, 303 (9.07%)
were associated with T2D at the 0.05 significance level, compared
to a mean of 6.2% [95% CI: 5.31% to 6.95%] in random
expanded eSNP sets (Z= 7.02; p = 1.10610212). In the DIA-
GRAM study, 9.2% were associated with T2D at the 0.05
significance level, compared to a mean of 7.3% [95% CI: 6.93% to
7.65%] in random expanded eSNP sets (Z= 10.40; p,10216).
However, the adipose eSNP set was not significantly more
enriched with small PT2D in the WTCCC study (p = 0.35;
Figure 2; Table 1). The lack of significance in the WTCCC
cohort was of interest, and given DIAGRAM contains both the
DGI and WTCCC cohorts, the intermediate enrichment of
DIAGRAM with respect to WTCCC and DGI reflects the strong
significance in DGI and lack of significance in WTCCC. It is of
particular note that one critical difference between the DGI and
WTCCC studies was the matching of DGI cases and controls for
BMI, whereas no such matching was done in the WTCCC study.
As the adipose network was derived from a mouse cross whose
parental strains are both on an ob/ob background, the BMI
matching in DGI may confer more biological similarities to the
cross design and hence better overlap. In addition, while the BMI
matching in DGI may enhance power to identify beta-cell loci,
rather than loci whose effect on T2D risk was mediated by obesity
[34], the BMI matching would not fully account for waist
circumference, where those individuals with increased waist
circumference compared to individuals with a similar BMI are
at increased risk of T2D, where omental adipose tissue is thought
to play a role [35].
Subnetwork Supported as Causal for T2D Further
Enhances eSNP Association with T2D
The genes comprising the adipose and islet co-expression
networks are not expected to uniformly affect T2D traits [12,13].
Figure 3A depicts the most highly connected expression traits in
the adipose network as a topological overlap map [30]. The
adipose network is composed of distinct subnetworks or modules
that emerge among the highly interconnected expression traits
[36]. Such co-expression subnetworks often contain genes of
related biological function [37]. For example, the purple
subnetwork in the adipose network was found to be the
subnetwork most significantly associated with T2D traits. The
genes comprising this subnetwork were enriched for the Panther
biological process lipid, fatty acid and steroid metabolism
(p = 4.4961028, Table 2). The first principal component of the
gene expression traits making up this subnetwork explained 45.6%
of the expression variation of the subnetwork and was strongly
Figure 3. Adipose T2D causal subnetwork and human supporting evidence. A) The adipose coexpression network is comprised of 9,900
gene expression traits. The purple subnetwork comprised of 159 genes is highlighted as the subnetwork most enriched for genes supported as causal
for T2D. B) LOD score plots for plasma insulin (solid black), Me1 adipose expression (solid red), Anxa2 adipose expression (solid blue), Bcl2l10 adipose
expression (solid cyan), 2310046806Rik adipose expression (solid black), Car12 adipose expression (solid green), Paqr9 adipose expression (solid
magenta), C730029A08Rik adipose expression (dashed red), Poclce2 adipose expression (dashed blue), and adipose expression traits linking to this
region in trans (grey), all measured in the B66BTBR cross. C) The T2D adipose causal subnetwork is enriched for genes supported as having a causal
relationship with plasma insulin levels in the B66BTBR cross (blue nodes). The white nodes represent genes in the T2D adipose causal subnetwork
not supported as causal for insulin traits in the B66BTBR cross. D) OGTT curves for Me12/2 (Male n = 19; Female n = 14) and wild-type control (Male
n = 25; Female n = 16) mice (p = 3.1661024 for male OGTT AUC and p= 1.8461023 for female OGTT AUC; overall sex adjusted difference
p= 7.3061028). E) The T2D adipose causal subnetwork is enriched for genes in the Me12/2 adipose gene expression signature (orange nodes). The
white nodes represent genes in the purple subnetwork not in the Me12/2 adipose gene signature.
doi:10.1371/journal.pgen.1000932.g003
Networks of eSNPs
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positively correlated with several T2D clinical traits measured in
the B66BTBR mice: number of islets (R=0.52, p,1610270),
plasma insulin levels (R=0.70, p,1610270), and plasma glucose
levels (R=20.57, p,3.9610241).
We next applied a previously described method for inferring
causal relationships between the expression traits and T2D traits
with respect to genetic loci controlling for the islet count
phenotype and plasma glucose and insulin levels [24]. We have
previously shown that subnetworks under the control of genetic
loci that are also associated with disease traits can be enriched for
genes predicted to cause disease trait variation [38]. The purple
subnetwork was supported as the most strongly causal subnetwork
for the T2D traits in the adipose coexpression network in the
B6xBTBR cross (referred to here as the T2D adipose causal
subnetwork), with 36% (Fisher Exact Test p = 5.26610268), 27%
(Fisher Exact Test p = 1.40610250) and 29% (Fisher Exact Test
p = 1.55610244) of the genes in this subnetwork supported as
causal for plasma insulin levels, plasma glucose levels, and number
of islets, respectively (Figure 3C, Table 2, Table S2). Therefore,
while there are many subnetworks identified in the adipose
network, they are not all associated with T2D traits, and in the
context of the B6xBTBR cross there is a single subnetwork in
adipose that is very significantly enriched for genes causally
associated with T2D.
Given the strong causal relationship inferred between the T2D
adipose causal subnetwork and T2D in the BTBRxB6 cross, we
tested whether omental adipose eSNPs corresponding to genes in
this subnetwork were more significantly enriched for association to
human T2D compared to the adipose network filtered eSNP sets.
Astonishingly, of the 101 SNPs in the expanded eSNP set that
were associated with the expression of genes in the T2D adipose
causal subnetwork, 37 (37%) corresponded to PT2D,0.05 in the
DGI study, compared to an average of 9.0% SNPs ([95% CI:
3.44% to 14.63%]) in the matched random SNP sets sampled
from the adipose network expanded eSNPs (p,10216), further
supporting that this subnetwork is an important network for
human T2D, and further supporting that the this causal
subnetwork may reflect important molecular states associated
with increased omental fat mass and the link of this increased fat
mass to T2D. Similar enrichments were observed in the
DIAGRAM study, although as in the case of the adipose network,
the WTCCC enrichment was not significant (Table 1, Figure 2).
Tissue Specific eSNP Set Enrichment
In addition to the dramatic enrichments observed in restricting
attention to those human omental eSNPs corresponding to genes
in the B6xBTBR T2D adipose causal subnetwork, the eSNPs
generated from the other tissues and from all tissues combined
were also enriched for lower PT2D values. The increasing
enrichment trend was consistently observed from all tissue-GWAS
combinations (Figure S2). While the enrichment magnitude and
significance levels were somewhat tissue dependent, there were no
profound differences among liver, omental fat and subcutaneous
fat tissue eSNPs, possibly reflecting that all three tissues are
metabolically active and important in obesity and diabetes.
When comparing eSNPs identified in independent tissues from
the same cohort, 72% of the cis eSNPs identified in liver, 79% of
those found in omental adipose, and 81% from subcutaneous
adipose were also found in the other two tissues: 2,189, 2,286 and
1,999 tissue specific eSNPs were identified in liver, omental
adipose, and subcutaneous adipose, respectively. This is consistent
with previous findings on tissue-specific effects [13,39]. Because
there is reduced numbers of eSNPs represented in the tissue
specific sets, there is reduced power overall to detect enrichments.
We note that in cases where the WTCCC enrichments were not
significant in restricting attention to omental eSNPs, the
enrichments were significant when focusing on eSNPs over all
tissues combined. By pooling eSNPs from liver and adipose tissue,
our main aim was to increase power to detect enrichments by
increasing the number of eSNPs. While pooling of eSNPs from the
three tissues was a first step in our analysis, restricting attention to
the most disease relevant tissue in this case resulted in the most
dramatic enrichment, highlighting the importance of the mouse
cross in identifying the most causal subnetworks for disease in the
most disease relevant tissue corresponding to the disease relevant
tissues we had available in the human cohort.
eSNP Filtering Methods Lead to the Identification of ME1
as a T2D Susceptibility Gene
While the enrichment of eSNPs associated with genes in the
T2D adipose causal subnetwork was encouraging (37% of the
eSNPs in this subnetwork associated with T2D at the nominal 0.05
significance level), the effect sizes were all small, providing for very
little power to prioritize the list for direct experimental validation
based on the human association data alone. Given the number of
Table 2. Gene sets significantly over-represented in the mouse and human T2D adipose causal subnetwork.
Gene set type Gene set description Mouse subnetwork (N= 159)
Gene set counta
overlap (Enrichment p valuec,
fold enrichmentb)
Panther biological process Lipid, fatty acid and steroid metabolism 729 27 (4.95610210, 4.1)d
Causal gene sets Genes supported as causal for plasma insulin 432 57 (5.26610268, 29.3)f
Genes supported as causal for plasma glucose 357 44 (1.40610250, 27.4)f
Genes supported as causal for number of islets 605 47 (1.55610244, 17.3)f
Single gene perturbation experiments Me12/2 versus wild-type signature 2958 32 (9.2561027, 2.4)f
aThe number of genes represented on the mouse array that mapped to orthologs in human.
bThe overlap count is computed by counting the number of transcripts in the intersection between the indicated gene set and the subnetwork. The fold enrichment is
computed as the observed overlap count divided by the expected overlap count, estimated by multiplying the subnetwork gene count by the fraction ‘gene set count
divided by total gene count’.
cNominal p values represent the significance of the Fisher Exact Test statistic under the null hypothesis that the frequency of the indicated gene set is the same between
a reference set of all genes represented on the array and the set of genes comprising the subnetwork.
dTotal gene count is 17,413.
fTotal gene count is 35,345 transcripts on the array.
doi:10.1371/journal.pgen.1000932.t002
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putative causal genes represented in this module, we could not
carry out experimental validation on all of them. Therefore, we
integrated the mouse and human data to prioritize the list of T2D
susceptibility genes for validation. To identify susceptibility genes
for validation, we identified genes in the T2D adipose causal
subnetwork that harbored DNA variations in mouse and human
that associated with its expression levels and that were supported
as causal for T2D [24]. This is a natural filter to apply, given DNA
variations that directly affect the activity of a gene in multiple
species, and that in turn are supported as causing variations in
disease traits [24], strongly implicate such genes as affecting
disease susceptibility [14]. Specifically, for validation purposes, we
focused on genes meeting the following three criteria: 1) adipose
expression levels in the B6xBTBR cross were associated with
genotypes for markers proximal to the gene of interest (i.e., genes
that gave rise to cis eQTL); 2) supported as causal for T2D traits
using a previously described statistical procedure to infer causal
relationships between expression and clinical traits [24]; and 3)
gave rise to an adipose cis-eSNP in humans that associated with
T2D in human GWAS. Application of this filter identifies those
expression traits in the B6xBTBR cross and human GGE cohorts
that are perturbed by cis DNA variation, and that in turn associate
with T2D traits, directly supporting the genes as causal for T2D in
the B6xBTBR cross and the human population.
Of the 159 expression traits in the T2D adipose causal
subnetwork, 117 gave rise to cis or trans expression QTL (eQTL)
in a distinct region on chromosome 9 (from 65Mb to 95Mb of the
chromosome). However, only 8 of these genes were identified with
strong adipose cis-eQTLs (i.e., the structural genes were located
within the chromosome 9 linkage region). Further, 5 of these 8
genes (Anxa2, Bcl2l10, C730029A08Rik, Me1, Paqr9) were support-
ed by the mouse data as causal for T2D traits (Figure 3B). Among
these, only human ME1 adipose expression was associated with at
least one cis-eSNP that was also nominally associated with T2D in
the DIAGRAM study (PT2D= 0.002) (Figure S3). Therefore, while
Me1 was supported as causal in the B6xBTBR cross, it was one of
hundreds of genes supported as causal for T2D traits, but then the
only gene of those hundreds whose expression in humans
associated with a SNP that also associated with human T2D.
The role of Me1 in obesity [40–42], energy homeostasis [43]
and diabetes [44] has been well documented in the literature.
Encoding a cytosolic NADP(+)-dependent enzyme involved in the
formation of pyruvate from malate, it produces NADPH to supply
reducing equivalents for lipogenesis, thus siphoning the reducing
equivalents originally derived from glycolysis as NADH to
NADPH for fatty acid synthesis [45]. Me1 is co-regulated together
with fatty acid synthetic enzymes by Chrebp and Srebp-1c and is
therefore described as a lipogenic enzyme. Further, we recently
provided direct experimental support for the involvement of Me1
in obesity-related phenotypic characteristics and in gene networks
associated with obesity using a Me1 knockout (Me12/2) mouse
model [31].
Here, we extended the validation experiment to T2D related
traits. As shown in Table 3, the Me12/2 mice fed a high fat diet
(HFD) demonstrate significantly lower insulin levels compared to
the controls (p = 1.2361029), thus validating our prediction. In
addition, the Me12/2 mice showed lower serum glucose levels
(p = 3.3061026) and an improved glucose tolerance at week 23
(Figure 3D), with a 29.5% decrease in the area under the oral
glucose tolerance test (OGTT) curve (AUC) relative to wild-type
mice (p= 7.3061028). All of these lines of evidence support a
diabetes-resistant phenotype in Me12/2 mice. Furthermore, the
Me12/2 mice also possessed significantly improved lipid profiles
including lower total cholesterol (p = 2.1961023) and triglyceride
(p = 1.4061027) levels. Consistent with the lower body fat
reported earlier [31], the serum leptin levels were also significantly
lower in the Me12/2 mice than in the controls. Therefore, the
Me12/2 mice appeared to be resistant to both diabetes and
obesity development.
In order to explore the mechanisms underlying the observed
phenotypic changes in the context of the subnetworks identified by
the eSNP filtering method, we constructed a single gene
perturbation gene expression signature for Me1, comprised of
2,958 genes, by identifying adipose genes differentially expressed
between wild type and Me12/2 male mice. The molecular
perturbation signature can serve as an important molecular
validation that a putative causal gene underlying a linkage region
associated with disease is in fact one of the genes in the linkage
region explaining the linkage signal [46]. We found that the Me1
perturbation signature was significantly enriched for many
metabolic pathways, including insulin receptor signaling pathway
(p = 2.2761025), fatty acid (p = 5.4961026), amine (p =
8.6761028), lipid (p = 5.4761027), and monocarboxylic acid
metabolic processes (p = 4.7361027; similar to the purple mouse
subnetwork depicted in Figure 3A). The Me1 perturbation
signature was significantly enriched for expression traits in the
T2D adipose causal subnetwork: 32 genes overlapped this network
whereas only 13 would have been expected by chance, a greater
than 2-fold enrichment (Fisher Exact Test p= 2.9561027;
Figure 3E, Table 2). This serves as an important molecular
Table 3. Comparison of metabolic traits between Me12/2 mice and wild-type controls.
Male Female
Trait
Wild typea
(n =25)
Me12/2
(n = 19)
Percentage
change (%)
Wild type
(n =16)
Me12/2
(n =14)
Percentage
change (%)
Difference
p valueb
OGTT AUC (min (mg?ml21)) 424.5(117.4) 299.4(36.9) 229.5 350.2(116.3) 239.8(23.8) 231.5 7.3061028
Glucose (mg?ml21) 2.4(0.6) 1.8(0.2) 224.9 1.9(0.5) 1.6(0.2) 218.1 3.3061026
Insulin (mg?ml21) 10.9(6.1) 2.0(1.6) 281.5 2.9(2.2) 0.6(0.3) 278.9 1.2361029
Leptin (mg?ml21) 11.2(3.3) 6.1(2.6) 245.4 4.6(4.0) 2.4(2.4) 247.8 1.6961026
Cholesterol (mg?ml21) 2.2(0.4) 1.9(0.5) 213.8 1.3(0.3) 1.0(0.1) 222.7 2.1961023
Triglycerides (mg?ml21) 2.3(1.0) 1.2(0.4) 248.6 1.4(0.4) 1.0(0.1) 226.9 1.4061027
aPresented as mean (SD).
bAll p values reported represent the significance of the t statistic under the null hypothesis that the difference in mean, sex-adjusted values between the Me12/2 and
wild-type groups is equal to 0.
doi:10.1371/journal.pgen.1000932.t003
Networks of eSNPs
PLoS Genetics | www.plosgenetics.org 7 May 2010 | Volume 6 | Issue 5 | e1000932
validation of the eSNP filtering method and confirms the causal
nature of a gene identified through this approach, Me1.
Discussion
GGE studies provide the necessary information to infer causal
relationships among genes and between genes and clinical traits,
leading to the construction of gene networks that underlie diseases
of interest [12–14,24,25]. Three fundamental advances presented
herein significantly extend this earlier work: 1) to our knowledge,
we have demonstrated for the first time that SNPs that associate
with human gene expression traits in metabolically relevant tissues
are enriched for associating with T2D in multiple T2D studies; 2)
the enrichment of eSNPs associating with T2D over randomly
selected SNPs dramatically increased as we restricted attention to
eSNPs corresponding first to genes comprising the co-expression
network from adipose tissue isolated from a mouse population
segregating T2D traits, and then to genes comprising a specific
adipose subnetwork strongly supported as causal for T2D-
associated traits; and 3) we demonstrated directly that causal gene
networks provide a path to functionally informing on genetic loci
found in GWAS to associate with disease. The inability of GWAS
studies to directly elucidate the causal genes and their function
with respect to disease is now widely accepted as a problem in
search of a solution; we provide one possible solution. Our results
taken together support the idea that common forms of disease like
T2D are emergent properties of networks that respond to wide-
spread variation (genetic and environmental), as opposed to the
result of single hits to single genes. The eSNPs for genes in the
T2D adipose causal subnetwork that were enriched for associating
with T2D were too subtly associated with the disease to be
identified in a classic GWAS, due to lack of power. However, the
associations were detectable by reducing the number of SNPs
tested in a GWAS, given the focus was on those SNPs that
associate with the expression of genes in a subnetwork supported
as causal for the disease of interest.
The causal reasoning we have used to identify causal
relationships between genes and disease traits refers to a statistical
inference procedure in which statistical associations between
changes in DNA, changes in expression, and changes in complex
phenotypes like disease are examined for patterns of statistical
dependency among these variables that support directionality
among them, where the directionality then provides the source of
causal information. This stands in contrast to the classic use of
causality in molecular biology or biochemistry, where causality
between two proteins implies that one protein has been
determined experimentally to physically interact with or to induce
processes that directly affect another protein, and that this in turn
leads to a phenotypic change of interest. Therefore, experimental
validation in this setting is critical. Towards that end, ME1 was
identified as a putative driver of a gene subnetwork containing key
regulators of lipogenesis and was then validated in vivo as a gene
capable of modulating multiple T2D traits. The genes whose
adipose expression levels change in response to knocking out Me1
were enriched for genes that 1) fell in this subnetwork, and 2) were
supported as causal for T2D in this mouse T2D population. As we
have previously detailed, this provides direct experimental support
for the gene as a causal regulator of the subnetwork [12,24,46].
The T2D adipose causal subnetwork contains several co-expressed
genes encoding key lipogenic enzymes, such as fatty acid synthase
(Fasn), ATP citrate lyase (Acly), stearoyl-Coenzyme A desaturase 2
(Scd2), lanosterol synthase (Lss), farnesyl diphosphate synthetase
(Fdps), and phospholipase A2, group V (Pla2g5). The abnormal
liporegulation found in obesity has previously been implicated in
the pathogenesis of diabetes [47,48], especially around the
deleterious effects of the elevated levels of triglycerides in
peripheral tissues, referred to as ‘‘lipotoxicity’’. Excess circulating
fatty acids present during obesity can accumulate in skeletal
muscle tissues, contributing to insulin resistance [49,50,51].
Another organ negatively impacted by lipotoxicity is the
pancreatic islets, where elevated fatty acid levels have been shown
to contribute to b-cell apoptosis, a process thought to involve the de
novo formation of ceramide and increased nitric oxide (NO)
production, resulting in impaired glucose-stimulated insulin
secretion [52,53,54].
Due to the key role played by Me1 in fatty acid synthesis, we
hypothesized that a genetic knockout of malic enzyme in mice fed
a high-fat diet would severely perturb this pathway. This would in
turn lead to a decrease in circulating free fatty acids and
triglycerides, a diminished ectopic triglyceride deposition, and
consequently an improved insulin sensitivity profile. Indeed, both
male and female Me12/2 mice exhibited dramatically improved
responses to an OGTT (Figure 3D), as well as significantly lower
plasma triglyceride levels (Table 3; see Text S1 for further
discussion of Me1 and diabetes).
It is important to note that while an adipose subnetwork
strongly supported as causal for diabetes in an experimental mouse
population demonstrated increased T2D eSNP enrichment when
compared to the adipose network as a whole, only moderate
enrichments were observed for all eSNPs and adipose-specific
eSNPs. One possible explanation could be the limited coverage of
eSNPs. For instance, certain GWAS SNPs may not affect gene
expression, rather, they may alter post-transcriptional mechanisms
such as mRNA splicing, or protein function. In other words, eSNP
selection based on the GGE might have missed classes of
important functional GWAS SNPs, and thus caused a loss of
power. Additionally, our GGE cohorts may not have been
appropriately powered to pick up all relevant eSNPs for T2D.
The eSNPs used in this study are primarily from liver and adipose
tissues. Although these are relevant tissues for T2D, other key
tissues such as islet, muscle, and even brain were not available for
eSNP discovery and hence a significant percentage of tissue-
specific eSNPs were missing from our analysis. This emphasizes
the importance of tissue selection for the success of this type of
approach. Since many aspects of disease pathology are confined to
certain tissues, the ability for eSNPs to inform on the biology relies
on having a tissue-appropriate set of eSNPs. Related to this is our
characterization of human gene expression traits in non-T2D
individuals, which may have caused us to miss many relevant T2D
eSNPs. Our first GGE cohort was a population-based random
sample, while the second was an obese cohort, hence neither
represents an appropriately powered T2D-specific cohort. Finally,
the sample sizes of the GGE cohorts were not powered well
enough to pick out the types of modest effects found in large
GWAS studies. In our analysis, we pooled the eSNPs from the two
cohorts in the three tissues as a starting point, mainly to improve
power to observe pathway-specific signals. Many of these caveats
associated with limited coverage of eSNPs are being addressed via
increased funding for very large GGE studies. Therefore, we think
the results realized here provide the beginning lines of evidence
that eSNPs may in fact generally be enriched with disease
associating SNPs.
The set of eSNPs used in our analyses were identified at a false
discovery rate (FDR),10%. The motivation for selecting what
could be considered a high FDR threshold was to increase the
number of eSNPs to enhance the power to detect patterns of
enrichment, as opposed to limiting attention to only the highest
confidence single genes associated with disease. We also consider
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the possibility that the effective FDR decreases as we apply the
filtering process of restricting attention to eSNPs whose associated
genes are present in co-expression networks and subnetworks
supported as causal for diabetes traits. We therefore suspect that
this filtering process enhances the enrichment for T2D association
primarily by restricting eSNPs to disease susceptibility gene
networks, although a reduced effective FDR may also play a role.
Indeed, while we have singled out a single gene, Me1, as playing
a causal role in this network, the true value of the currently
described eSNP filtering approach is in its ability to identify disease
susceptibility networks rather than single SNPs or genes
traditionally identified through GWAS. In fact, the knockout gene
expression signature forMe1 was significantly enriched for genes in
the T2D adipose causal gene network, providing direct experi-
mental evidence of the high degree of interconnectivity within this
network, where perturbing one gene supported as causal for
disease affects many other genes supported as causal in this
network, as we have previously shown for other disease causal
networks [12,46]. We have shown for the first time that SNPs that
are associated with transcript abundance are more likely to
associate with a complex trait as well. This type of approach
provides a way to reduce the dimensionality of the DNA variation
space and can help us reconsider how to map complex disease
using gene expression traits. This approach can also help prioritize
GWAS findings, for instance, by including the eSNPs correspond-
ing to genes in causal disease networks in testing for epistasis or for
consideration in future genetic association studies.
GWAS will continue to deliver high-confidence correlations
between DNA changes at a given locus and disease-associated
traits of interest. Our understanding of the individual genes at
these loci that alter disease susceptibility and the broader context
in which they operate can be enhanced by leveraging studies that
seek to map the genetics of gene expression. Generating large-scale
molecular profiling data sets in both human and experimental
segregating populations potentially provides additional power to
elucidate not only the genetic basis of disease, but also the impact
the genetic basis of disease has on molecular networks that in turn
drive physiological states associated with disease. Diabetes
pathogenesis involves many pathways operating in different tissues
and distinct physiological processes (blunted insulin signaling and
failure of beta cells to compensate by producing more insulin).
Therefore, the integration of large-scale molecular profiling,
genotypic, clinical, and other biologically relevant data will be
critical if we hope to understand more fully how genetic and
environmental perturbations lead to complex traits like disease.
Integration of a diversity of data in this setting will be key, since no
single data dimension will provide the complete answer.
Methods
eSNP Processing and Analysis
For the liver-specific GGE cohort, more than 39,000 transcripts
were profiled and 782,476 unique SNPs were genotyped in more
than 400 human liver samples [12]. In this cohort, the genetics of
gene expression analysis resulted in the detection of 3,309 unique
eSNPs at an FDR,10% [14]. The eSNP processing and analysis
were carried out as previous described [14]. All expression data
have been deposited in the Gene Expression Omnibus database
under accession number (GSE9588) [14].
The second multi-tissue GGE cohort was comprised of patients
who underwent RXY gastric bypass surgery. Liver, subcutaneous
adipose and omental adipose tissues were collected from each
patient at the time of surgery at Massachusetts General Hospital.
Genomic DNA was extracted from liver tissue for each patient,
and total RNA was extracted from liver, subcutaneous adipose and
omental adipose tissues. Each RNA sample was profiled on a
custom 44K Agilent array. RNA processing methods are detailed
in Text S1. Each DNA sample was genotyped on the Illumina
650Y BeadChip array. We successfully genotyped 950 samples.
Identity by state (IBS) analysis was performed to identify related
individuals within this cohort. Eighteen parent-offspring, 6 sibling
and 8 second degree relatives were identified, and 4 of these were
related as trios. Twenty-eight individuals were removed to
eliminate IBS in the dataset, leaving 922 samples for use in the
analysis. Demographic information including age, race, gender,
height, type of surgery and year of surgery were collected for each
patient (Text S1). We required that the minor allele frequency for
a SNP be .5% in order to be considered in the analyses.
Cis and trans acting expression quantitative trait loci (eQTLs)
were identified using a method similar to that previously described
[14]. The cis eQTL for a given expression trait were defined as
those with corresponding SNPs located within 1 megabase (Mb) of
the transcription start or stop of the associated structural gene. All
other associations were considered trans. SNP associations were
identified using the Kruskal-Wallis test. The association p values
were adjusted to control for testing of multiple SNPs and
expression traits using an empirically determined FDR con-
strained to be,10%. For cis eQTL, we only tested for associations
to SNPs that were within 1 Mb of the annotated start or stop site
of the corresponding structural gene. The empirical FDR
permutations were restricted to SNPs within the cis regions. In
the case of trans eQTL, all SNPs were tested for association to each
of the expression traits. Where SNP associations were identified to
the same trait in high LD with each other, the SNP with the most
significant p value was reported.
When comparing eSNPs identified in independent tissues from
the same cohort, 72% of the cis eSNPs identified in liver, 79% of
those found in omental adipose and 80.5% from subcutaneous
adipose were also found in the other two tissues. Of the eSNPs
detected, 2,189, 2,286 and 1,999 were specific eSNPs to liver,
omental adipose and subcutaneous adipose, respectively. When
compared to the set of liver eSNPs from the first cohort there was a
66% overlap in eSNPs indentified between the two studies. The set
of eSNPs used in the paper is the combined set of eSNPs from the
four sources, comprising 18,785 unique eSNPs in total.
Statistical Analysis
Statistical methods for evaluating eSNP set enrichment.
We used a matched random sampling strategy to assess whether a
given set of eSNPs was more likely to associate with T2D than
randomly selected sets of SNPs with equal size, similar location to
human genes, similar MAF distributions, and similar LD structures.
For cis-eSNPs, we first required that the random SNP pool be
composed of SNPs located within 1MB of human gene regions and
withMAF.5%.We then binned the random SNPs into five groups
according to their MAF: 5–10%, 10–20%, 20–30%, 30–40% and
40–50%. For each cis-eSNP, we randomly selected a genotyped
SNP from the same MAF group in each random sample. A similar
procedure was employed for trans-eSNPs, except that we did not
require the random SNP be within 1MB of a gene region. When
there were multiple eSNPs located in one LD block, we randomly
selected the same number of SNPs (matched according to MAF and
position with respect to gene region) that were in the LD block
corresponding to the matched eSNPs. This process was repeated
100,000 times. For each random SNP set, we counted the
percentage of SNPs with GWAS p,0.05, P10:05 . . .P
100,000
0:05 , and
from this constructed the null distribution. We then compared the
observed percentage of eSNPs with GWAS p,0.05 to the null
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distribution in order to estimate the enrichment p value. An
approximation method, which was used to increase the enrichment
p value resolution, is detailed in Text S1.
Statistical methods for evaluating eSNP expanded set
enrichment. We first used the matched random sampling
strategy described above to get a random set of SNPs that matched
the eSNP set. The eSNP set expanded by including all SNPs in
strong LD with the eSNPs. A SNP was considered in strong LD
with an eSNP if the correlation between the two SNPs was .0.89.
The random SNP set was expanded in a similar fashion by
including SNPs that were correlated with a given SNP (R.0.89).
We required the final size of the expanded random set of SNPs to
be within 610% of the size of the expanded set of eSNPs. This
requirement ensured that the expanded eSNP set would not be
biased relative to the expanded random SNP set by including
more SNPs with a richer LD structure, thereby having a greater
probability of associating with T2D and expression traits, even in
cases where the expression and T2D are completely genetically
independent. By forcing the expanded set sizes to be equal we
removed the potential confounding effect caused by LD structure.
Therefore, the random sampling scheme produced sets of SNPs in
which the LD, set size, and location with respect to protein coding
genes, and MAF distributions matched those of the expanded
eSNP sets. The process was again repeated 100,000 times. The
enrichment p values were then derived as described above.
Statistical methods for evaluating an enrichment increase
when comparing two sets of eSNPs. When assessing if one set
of eSNPs (size =M) was more enriched for small PT2D than a
second eSNP set (size =N, N.M), we compared between the two
classes directly. For each cis (or trans) eSNP in the second set, we
randomly selected a cis (or trans) eSNP from the first set such that
it fell in the same MAF group as the first. When there were
multiple eSNPs located in one LD block in the second set, we
randomly selected the same number of eSNPs from the first set
from the corresponding LD block. For each random sample we
counted the percentage of sampled eSNPs with PT2D,0.05. The
proportion of times this percentage exceeded the observed
percentage of the second eSNP set (with PT2D,0.05) was taken
as the estimate of the p value under the null hypothesis that the
two sets of eSNPs were similarly enriched (vs. the alternative
hypothesis that the second eSNP set was more enriched than the
first. Comparison of two expanded eSNP sets proceeded in a
similar fashion, where again all SNPs that were significantly
correlated (R.0.89) with any of the randomly identified eSNPs in
each random sample were included.
Given the above procedures, when comparing if the adipose
network eSNPs were more enriched for low PT2D than all eSNPs,
we compared the adipose network eSNPs and equal-sized groups
of random eSNPs. When comparing if the T2D adipose causal
subnetwork eSNPs were more enriched for low PT2D than the
adipose network eSNPs, we compared the subnetwork eSNPs and
equal-sized groups of random adipose network eSNPs. This
answered directly whether the SNP filtering process increased
enrichment for small PT2D.
Generation of the B66BTBR Cross F2 Mice
554 F2 mice were generated in a cross between two inbred
strains, both containing the ob mutation at the leptin locus:
C57BL/6 ob/ob and BTBR ob/ob (referred to as the B66BTBR
cross) [27]. All F2 animals were maintained on a chow diet for ten
weeks and were clinically characterized with respect to obesity-
and diabetes-related traits at four, six, eight and ten week time
points. Further details regarding the plasma glucose and insulin
measurements, as well as islet isolation procedures, can be found in
Keller et al. [29]. At the time of necropsy, gonadal white adipose
tissue was collected from 497 mice. RNA was prepared using the
same methods as described previously [29] and hybridized to an
Agilent custom murine gene expression microarray.
Reconstruction of the Adipose Coexpression Network
Of the 39,600 transcribed sequences represented on the
microarray, the top 25 percent rank ordered by degree of
differential expression in the adipose tissue were included in the
reconstruction process [29]. These gene expression traits were
used to construct weighted, co-expression subnetworks comprised
of the most highly connected nodes from each tissue and sex
using previously described methods [30] (Text S1). QTL were
detected for each of the expression and metabolic traits using a
forward stepwise regression procedure [55,56]. QTL with
pleiotropic effects on expression and metabolic traits were
identified using a multivariate likelihood test [24,57]. The
QTL, expression, and metabolic trait data were then integrated
to assess whether each expression trait was supported as having a
causal relationship with each of the metabolic traits, with respect
to QTL detected with pleiotropic effects on the expression and
metabolic traits [24].
Construction and Phenotypic Characterization of
Me12/2 Mice
A naturally occurring mouse mutant deficient in Me1 enzymatic
activity was first reported by Lee et al. in 1980 [58]. The detailed
methods for breeding, genotyping, and characterization of the
Me12/2 mice have been described previously [31,59]. Littermate
male Me12/2 and wild-type mice were challenged with a high fat
diet (HFD) starting at 7–8 weeks of age for 19 weeks. An oral
glucose tolerance test (OGTT) was performed at week 23–24 of
age and terminal blood serum was collected at week 26–27 of age.
For females, HFD was initiated at week 8–10 and continued for 19
weeks. OGTT was performed at week 26–28 of age and terminal
serum samples were collected at week 27–28 of age. Mice were
euthanized at the end of the HFD period. For OGTT, glucose was
administered at 2g/kg of mouse mass via oral gavage, mice were
fasted 18 hours Prior, and glucose levels were measured using a
OneTouch Ultra glucometer (LifeScan, Inc, Milpitas, CA) at 0,
30, 60, 90, and 120 min. Serum was collected from blood using
Becton Dickson (Franklin Lakes, NJ) Microtainer tubes with SST.
Insulin and leptin were measured using Millipore’s (Billerica, MA)
Multiplexed Biomarker Immunoassay for Luminex xMap using a
Bio-Rad’s (Hercules, CA) Bio-Plex machine. The other serum
parameters were measured using a colorimetric assay. Triglycer-
ides were measured at OD 510 nm using reagents from Roche
Diagnostics (Indianapolis, IN). Cholesterol was measured using
reagents from Stanbio (Boerne, TX) at OD 510 nm as well.
Identification of Adipose Expression Signature in
Me12/2 Mice
The gonadal white adipose tissues were collected from 10 male
Me12/2 mice and 10 male littermate wild-type (wt) control mice.
The detailed methods have been described previously [31,59].
The adipose tissues were homogenized and total RNA extracted
using Trizol reagent (Invitrogen, CA). Three micrograms of total
RNA was reverse transcribed and labeled with either Cy3 or Cy5
fluorochrome. Labeled complementary RNA (cRNA) from each
animal was hybridized against a pool of labeled cRNAs
constructed from equal aliquots of RNA from the control animals
using Agilent arrays consisting of 39,556 non-control probes that
represent 37,687 genes. Arrays were quantified on the basis of spot
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intensity relative to background, adjusted for experimental
variation between arrays using average intensity over multiple
channels, and fitted to a previously described error model to
determine significance [60,61]. Gene expression measures are
reported as the ratio of the mean log10 intensity (mlratio). A
Student’s t-test was used to identify genes with significant
differences between Me12/2 animals and the corresponding wt
control mice. These genes were defined as ‘‘signature’’ genes,
representing the perturbed gene expression signature as a result of
single gene modification. The significance level was set to p,0.05.
The false discovery rate, calculated using Q-value [62], at this
significance level was 20%.
Supporting Information
Figure S1 SNP Sets Average log (PT2D) from the three GWAS.
The Y axis shows the average of 2log (PT2D). PT2D are from the
DIAGRAM, WTCCC, and DGI studies, from left to right. In
each GWAS cohort, from left to right, the first bar shows the
average of 2log (PT2D) of all studied SNPs; the second bar shows
the average of 2log (PT2D) of all eSNPs, the third bar shows the
average of 2log (PT2D) of adipose network eSNPs; the fourth bar
shows the average of 2log (PT2D) of T2d adipose causal
subnetwork eSNPs. In DIAGRAM, the second bar is higher than
the first (P = 1.3761029), the third is higher than the second
P=1.2161024), and the fourth is higher than the third
(P = 1.2261024). In the WTCCC study, the second bar is higher
than the first (P = 1.0161023), the third is not statistically
distinguishable from the second (P= 0.07), and the fourth is
marginally higher than the third (P= 0.04). In the DGI study, the
second bar is higher than the first (P = 5.8361023), the third is
higher than the second (P = 8.4861024), and the fourth is higher
than the third (P= 1.1761027).
Found at: doi:10.1371/journal.pgen.1000932.s001 (0.03 MB
DOC)
Figure S2 Enrichment of tissue-specific eSNP sets for SNPs
associated with T2D in three GWAS. The Y axis shows the
proportion of SNPs with PT2D,=0.05. From left to right, the
tissues liver tissue from liver-specific cohort, Massachusetts General
Hospital (MGH) liver tissue, MGH omental adipose, and MGH
subqutaneous adipose tissue. For each cluster of bars representing
a specific tissue in a specific GWAS, the first bar shows the
observed proportion of all studied SNPs, the second bar shows the
proportion of all eSNPs, the third bar shows the proportion of
adipose network eSNPs, and the fourth bar shows the proportion
of T2D adipose causal subnetwork eSNPs with PT2D,0.05.
Found at: doi:10.1371/journal.pgen.1000932.s002 (0.19 MB
DOC)
Figure S3 Regional plot of ME1 gene association with T2D in
the DIAGRAM GWAS. For ME1 gene region on chromosome 6,
genotyped and imputed SNPs are plotted with their meta-analysis
PT2D values (as 2log10 values) as a function of genomic position
(NCBI Build 35). SNPs associated with ME1 adipose expression
are shown as red triangles. The estimated recombination rates
(taken from HapMap) are plotted to reflect the local LD structure
around the associated SNPs and their correlated proxies (Y axis on
the right).
Found at: doi:10.1371/journal.pgen.1000932.s003 (0.04 MB
DOC)
Table S1 Tissue-specific eSNP discovery summary.
Found at: doi:10.1371/journal.pgen.1000932.s004 (0.03 MB
DOC)
Table S2 The T2D causal adipose subnetwork (purple module)
gene list, gene-trait correlations and causal genes.
Found at: doi:10.1371/journal.pgen.1000932.s005 (1.82 MB
DOC)
Text S1 Supplementary methods and discussion.
Found at: doi:10.1371/journal.pgen.1000932.s006 (0.18 MB
DOC)
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